Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.

ABSTRACT:

Importance

Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of adding tirzepatide vs prandial insulin to treatment in patients with inadequate glycemic control with basal insulin have not been described.

Objective

To assess the efficacy and safety of tirzepatide vs insulin lispro as an adjunctive therapy to insulin glargine.

Design, setting, and participants

This open-label, phase 3b clinical trial was conducted at 135 sites in 15 countries (participants enrolled from October 19, 2020, to November 1, 2022) in 1428 adults with type 2 diabetes taking basal insulin.

Interventions

Participants were randomized (in a 1:1:1:3 ratio) to receive once-

SUBMITTER: Rosenstock J 

PROVIDER: S-EPMC10548360 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature